Calamos Advisors LLC Crinetics Pharmaceuticals, Inc. Transaction History
Calamos Advisors LLC
- $16.8 Billion
- Q4 2024
A detailed history of Calamos Advisors LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Calamos Advisors LLC holds 14,402 shares of CRNX stock, worth $567,150. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,402
Previous 41,558
65.34%
Holding current value
$567,150
Previous $2.12 Million
65.32%
% of portfolio
0.0%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding CRNX
# of Institutions
241Shares Held
80MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$248 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$245 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$232 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$195 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$176 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.12B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...